All Stories

  1. Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease
  2. EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease
  3. Clinical Trial Outcomes in the Alzheimer's Disease Spectrum
  4. Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study
  5. Relationships of CSF biomarkers to cortical atrophy in early‐onset Alzheimer's disease
  6. Cognitive dispersion profiles and prediction of cognitive change in early‐onset dementias: Results from LEADS
  7. Criterion and convergent validity of plasma biomarkers in early‐onset Alzheimer's disease: Initial findings from LEADS
  8. Relationship between age and severity of cognitive impairment at diagnosis for early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
  9. Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease
  10. Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease
  11. Tablet‐based Cognitive Assessment Tool (TabCAT) in a multisite study of early‐onset Alzheimer's disease
  12. Estimation of reference curves for brain atrophy and analysis of robustness to machine effects
  13. The financial consequences of undiagnosed memory disorders
  14. First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population
  15. Speech production as an artificial intelligence-based ‘process’ measure of cognition sensitive to mild cognitive impairment and Alzheimer’s disease
  16. Safety, Cognitive, and Behavioral Outcomes in Patients with Dementia with Lewy Bodies Treated with Nilotinib
  17. Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease
  18. Mouse models of Anti-Aβ immunotherapies
  19. Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials
  20. Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts
  21. Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer’s disease: a neuropsychological data-driven approach
  22. Dissociable spatial topography of cortical atrophy in early‐onset and late‐onset Alzheimer's disease: A head‐to‐head comparison of the LEADS and ADNI cohorts
  23. Differences in baseline cognitive performance between participants with early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
  24. Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS
  25. Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease
  26. The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials
  27. Alzheimer disease–related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study
  28. Aging as a target for the prevention and treatment of Alzheimer’s disease
  29. Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder
  30. Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy
  31. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes
  32. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease
  33. The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort
  34. Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort
  35. An explainable machine learning model of cognitive decline derived from speech
  36. Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
  37. Influence of amyloid and diagnostic syndrome on non‐traditional memory scores in early‐onset Alzheimer's disease
  38. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
  39. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease
  40. Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study
  41. White matter hyperintensities are higher among early‐onset Alzheimer's disease participants than their cognitively normal and early‐onset nonAD peers: Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
  42. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort
  43. Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection
  44. Learning slopes in early‐onset Alzheimer's disease
  45. Matrix disequilibrium in Alzheimer’s disease and conditions that increase Alzheimer’s disease risk
  46. Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease
  47. CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice
  48. Inhibition of discoidin domain receptor (DDR)-1 with nilotinib induces autophagy and reduces inflammation and vascular fibrosis in Alzheimer’s disease
  49. Increasing access to cognitive screening in the elderly: Applying natural language processing methods to speech collected over the telephone
  50. CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice
  51. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
  52. Corrigendum: A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease
  53. Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV
  54. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
  55. Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease
  56. Low CD4 nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV
  57. Research Attitudes Questionnaire scores predict Alzheimer’s disease clinical trial dropout
  58. Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer’s Disease
  59. Acceptability of collecting speech samples from the elderly via the telephone
  60. A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease
  61. Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias
  62. Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
  63. Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease
  64. FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
  65. A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data
  66. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease
  67. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease
  68. Multimodal Hippocampal Subfield Grading For Alzheimer’s Disease Classification
  69. Non-coding variability at the APOE locus contributes to the Alzheimer’s risk
  70. Periprocedural Heparin During Endovascular Treatment of Tandem Lesions in Patients with Acute Ischemic Stroke: A Propensity Score Analysis from TITAN Registry
  71. The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
  72. White matter in different regions evolves differently during progression to dementia
  73. A blood-based signature of cerebrospinal fluid Aβ1–42 status
  74. Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model
  75. The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE ε4 in Mild Cognitive Impairment
  76. Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI
  77. A review of statistical methods in imaging genetics
  78. Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3
  79. Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles
  80. Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics
  81. Random forest prediction of Alzheimer’s disease using pairwise selection from time series data
  82. Predicting Alzheimer’s disease progression using multi-modal deep learning approach
  83. Neural activity during a simple reaching task in macaques is counter to gating and rebound in basal ganglia-thalamic communication
  84. Translating Alzheimer's disease–associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs
  85. Amyloid beta–positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity
  86. Association of CSF CD40 levels and synaptic degeneration across the Alzheimer’s disease spectrum
  87. Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling
  88. Functional signature of conversion of patients with mild cognitive impairment
  89. Medical Image Imputation From Image Collections
  90. QuickNAT: A fully convolutional network for quick and accurate segmentation of neuroanatomy
  91. MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders
  92. Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer’s Disease
  93. A δ Homolog for Dementia Case Finding with Replication in the Alzheimer’s Disease Neuroimaging Initiative
  94. Next Generation Sequencing Analysis in Early Onset Dementia Patients
  95. Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment
  96. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data
  97. A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative
  98. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study
  99. Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia
  100. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease
  101. Accurate risk estimation of β‐amyloid positivity to identify prodromal Alzheimer's disease: Cross‐validation study of practical algorithms
  102. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome
  103. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers
  104. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
  105. Cortico-basal-ganglia communication: Temporally structured activity for selective motor control
  106. A Novel Method to Estimate Long‐Term Chronological Changes From Fragmented Observations in Disease Progression
  107. Communicability disruption in Alzheimer’s disease connectivity networks
  108. Long-Term maintenance of anomia treatment effects in primary progressive aphasia
  109. Longitudinal Functional Brain Mapping in Supernormals
  110. Does treatment with resveratrol improve outcomes in patients with Alzheimer's disease?
  111. Polo-like kinase 2 phosphorylation of amyloid precursor protein regulates activity-dependent amyloidogenic processing
  112. Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease
  113. 11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease
  114. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
  115. The BIOCARD Index
  116. Exploratory Clustering for Patient Subpopulation Discovery
  117. 11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease
  118. Hexa (ethylene glycol) derivative of benzothiazole aniline promotes dendritic spine formation through the RasGRF1–Ras dependent pathway
  119. An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition
  120. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
  121. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models
  122. Corrigendum to “A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease” [Exp. Neurol. 252 (2014) 105–113]
  123. Correction: Megill et al., A Tetra(Ethylene Glycol) Derivative of Benzothiazole Aniline Enhances Ras-Mediated Spinogenesis
  124. Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype
  125. Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?
  126. A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease
  127. Cognitive Effects of Cancer and Its Treatments at the Intersection of Aging: What Do We Know; What Do We Need to Know?
  128. Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking
  129. Remediation and Prophylaxis of Anomia in Primary Progressive Aphasia
  130. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
  131. A Tetra(Ethylene Glycol) Derivative of Benzothiazole Aniline Enhances Ras-Mediated Spinogenesis
  132. Coexisting adult polyglucosan body disease with frontotemporal lobar degeneration with transactivation response DNA-binding protein-43 (TDP-43)-positive neuronal inclusions
  133. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease
  134. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease
  135. Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study
  136. Age-related loss of noradrenergic neurons in the brains of triple transgenic mice
  137. Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice
  138. Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic Errors
  139. ApoE Receptor 2 Regulates Synapse and Dendritic Spine Formation
  140. Validation of Consensus Panel Diagnosis in Dementia
  141. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines
  142. ApoE mimetic peptide decreases Aβ production in vitro and in vivo
  143. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease
  144. ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo
  145. X11α haploinsufficiency enhances Aβ amyloid deposition in Alzheimer's disease transgenic mice
  146. The cytoplasmic adaptor protein X11  and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement
  147. Amyloid-β-Induced Ion Flux in Artificial Lipid Bilayers and Neuronal Cells: Resolving a Controversy
  148. Amyloid-β Ion Channels in Artificial Lipid Bilayers and Neuronal Cells. Resolving a Controversy
  149. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
  150. Alzheimer's Disease
  151. P3-070 Adding FDG-PET to clinical history and examination improves the accuracy of dementia diagnosis
  152. P3-065 FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous
  153. O4-04-05 X11alpha/mint-1 modulates gamma-cleavage of amyloid precursor protein
  154. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?
  155. X11α impairs γ‐ but not β‐cleavage of amyloid precursor protein
  156. A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging
  157. Biomarkers of alzheimer’s disease and mild cognitive impairment: are we there yet?
  158. X11α modulates secretory and endocytic trafficking and metabolism of amyloid precursor protein: mutational analysis of the yenpty sequence
  159. Idiopathic Rapid Eye Movement Sleep Behavior Disorder Is a Harbinger of Dementia with Lewy Bodies
  160. Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease
  161. Inherited dementias
  162. Synergistic Effects of Munc18a and X11 Proteins on Amyloid Precursor Protein Metabolism
  163. Spontaneous intracranial hypotension causing reversible frontotemporal dementia
  164. ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways
  165. Stable β-Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice
  166. Differentiated Human NT2-N Neurons Possess a High Intracellular Content of myo-Inositol
  167. Alzheimer’s Disease in Man and Transgenic Mice
  168. The pathology of REM sleep behavior disorder with comorbid Lewy body dementia
  169. The Protease Inhibitor, MG132, Blocks Maturation of the Amyloid Precursor Protein Swedish Mutant Preventing Cleavage by β-Secretase
  170. Modulation of Amyloid Precursor Protein Metabolism by X11α/Mint-1
  171. FORUM What Persian Gulf War Syndrome?
  172. Identification of an Evolutionarily Conserved Heterotrimeric Protein Complex Involved in Protein Targeting
  173. The Chaperone BiP/GRP78 Binds to Amyloid Precursor Protein and Decreases Aβ40 and Aβ42 Secretion
  174. X11 Interaction with β-Amyloid Precursor Protein Modulates Its Cellular Stabilization and Reduces Amyloid β-Protein Secretion
  175. The X11α Protein Slows Cellular Amyloid Precursor Protein Processing and Reduces Aβ40 and Aβ42 Secretion
  176. Probable diffuse Lewy body disease presenting as REM sleep behavior disorder
  177. Vaccinia virus serves as an efficient vector for expressing heterologous proteins in human NTera 2 neurons
  178. Amyloids and Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation
  179. Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia
  180. Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides.
  181. Phospholipid/calcium-dependent protein kinase (protein kinase C) system: A major site of bioregulation
  182. Synthetic myelin basic protein peptide analogs are specific inhibitors of phospholipid/calcium-dependent protein kinase (protein kinase C)
  183. Correlation of the MMPI with Lumbosacral Spine Fusion Results
  184. Phospholipid-Sensitive Ca2+-Dependent Protein Kinase Preferentially Phosphorylates Serine-115 of Bovine Myelin Basic Protein
  185. Developmental studies of phospholipid-sensitive Ca2+-dependent protein kinase and its substrates and of phosphoprotein phosphatases in rat brain.
  186. Phospholipid-sensitive Ca2+-dependent protein kinase: a major protein phosphorylation system
  187. S-100 and Other Acidic Proteins Promote Ca2+-Independent Phosphorylation of Protamine Catalyzed by a New Protein Kinase from Brain
  188. Phospholipid-sensitive Ca2+-dependent protein kinase inhibition by R-24571, A calmodulin antagonist
  189. Polyamines inhibit phospholipid-sensitive and calmodulin-sensitive Ca2+-dependent protein kinases
  190. Comparative abilities of lanthanide ions La3+ and Tb3+ to substitute for Ca2+ in regulating phospholipid-sensitive Ca2+-dependent protein kinase and myosin light chain kinase
  191. Cobra polypeptide cytotoxin I and marine worm polypeptide cytotoxin A-IV are potent and selective inhibitors of phospholipid-sensitive Ca2+ -dependent protein kinase
  192. Basic Protein in Brain Myelin Is Phosphorylated by Endogenous Phospholipid-Sensitive Ca2+-Dependent Protein Kinase
  193. Inhibition by melittin of phospholipid-sensitive and calmodulin-sensitive Ca2+ -dependent protein kinases
  194. Methionine-enkephalin and morphine: Amount ejected microiontophoretically
  195. FUNCTIONAL ANATOMY OF BRACHIUM PONTIS